In the December 2015 issue, in the article “Predictive biomarkers for checkpoints, first tests approved,“ in Table 1, the highest threshold for PD-L1 positivity with the Ventana SP142 diagnostic for immune cells was given as 50%; the threshold is 10%. In addition, in Box 1, the name of the company Arcteris was misspelled as Arcteries. The errors have been corrected in the HTML and PDF versions of the article.

In the November 2015 issue, in the article “Drug makers target ubiquitin proteasome pathway anew,” pevonedistat (TAK-924) was mis-identified as TAK-243, and the synergies referred to were seen in preclinical experiments, not in phase 1. The first two sentences in the penultimate paragraph “Less selective, perhaps, is targeting the E1 ubiquitin-activating enzyme. But Takeda is exploring these targets in combination with other therapies, having seen what senior scientist Allison Berger describes as “striking synergy” between an E1 ubiquitin-activating enzyme inhibitor TAK-243, in phase 1, and azacytidine in patients with acute myelogenous leukemia” have been replaced with “Targeting pathways linked to ubiquitin-like proteins remains at an early stage, too. Takeda is exploring the potential of pevonedistat (TAK-924), a first-in-class inhibitor of Nedd8 activating enzyme, in several cancers. A combination trial with azacitidine is underway in acute myelogenous leukemia, following what senior scientist Allison Berger called “striking synergy” seen in preclinical experiments.” The errors have been corrected in the HTML and PDF versions of the article.